Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Omer Shvili who wrote (1204)	9/2/1998 8:24:00 AM
From: crysball	Read Replies (1) of 1491

Tamoxifen to be approved for Breast Cancer Prevention. This morning, NBC News nationally televised an interesting feature on the new role of Tamoxifen in preventing Breast cancer, and the planned FDA announcement approving it for limiited prophylactic indication in families with a genetic predisposition toward breast cancer . As with many other drugs the interesting aspect will be the off label usage. Tamoxifen is not without risk (as was carefully pointed out in the feature), but none the less it elevates the name of a long planned PARS product. Given PARS planned 1999 Phase I Tamoxifen study (subject to cash constraints for launch) this might help get some well deserved attention focused on the company. It will be interesting to see how PARS new financial PR organization plays this. Omer it might be interesting to obtain from NBC this clip for PARS.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next